{
    "Trade/Device Name(s)": [
        "GAL-1F Blood Glucose Monitoring System",
        "GAL-1F Blood Glucose Test Strips",
        "GAL-1F Pro Blood Glucose Monitoring System",
        "GAL-1F Pro Blood Glucose Test Strips"
    ],
    "Submitter Information": "Apex Biotechnology Corp.",
    "510(k) Number": "K142689",
    "Predicate Device Reference 510(k) Number(s)": [
        "K113547"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "NBW"
    ],
    "Summary Letter Date": "July 7, 2015",
    "Summary Letter Received Date": "July 8, 2015",
    "Submission Date": "Aug 04, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "GAL-1F meter",
        "GAL-1F Pro meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Test Strips",
        "Meter"
    ],
    "Document Summary": "FDA 510(k) summary for GAL-1F and GAL-1F Pro blood glucose monitoring systems for quantitative measurement of glucose in capillary whole blood.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from fingertips, forearm, or palm, as an aid to monitoring blood glucose levels in Diabetes Mellitus; GAL-1F system for single-patient lay use, GAL-1F Pro system for multiple-patient clinical use by healthcare professionals.",
    "fda_folder": "Clinical Chemistry"
}